BioCentury
ARTICLE | Company News

Pharmos sells ophthalmics to BOL

October 10, 2001 7:00 AM UTC

PARS sold its loteprednol etabonate (LE) ophthalmic business to Bausch & Lomb (BOL). BOL paid $25 million in cash for PARS's Lotemax and Alrex, which BOL already markets under a 1995 deal, and BOL is ...